2025 Psychopharmacology Pearls

Credit is awarded in the calendar year the assessment is completed. AAPP reports continuing credit for ACPE (CPE Monitor) and BCPP Recertification (BPS) within days of successful exam completion.

Target Audience

BCPPs who value and learn through case-based literature offering therapeutic advice on both evidence and longstanding clinical experience are the target audience for this product. New and experienced BCPPs desiring insights into the strategies of clinical decision-making used by expert clinicians will find value in this product as the articles focus on disease states, their pharmacotherapy, and the synthesis of solutions to challenges that require judgement(s) founded on evidence but modified or tempered by extensive clinical experience and practicalities of "real world" necessities.

Course Requirements

To satisfactorily complete the recertification programming and receive BCPP Recertification and ACPE credit, candidates must meet the following requirements:

  • Register for this course.
  • Complete the pre-test before starting the activity.
  • Review the full content of the activity and reflect upon its teachings.
  • Abide by a confidentiality and honesty statement requiring individual completion of the course.
  • Complete the post-test at the end of the activity no later than the closing activity date.
  • Complete an activity evaluation form.
  • Wait for an official review of exam questions within 4 weeks following the closing date.
  • Receive a passing grade (TBD).
  • Partial credit is not provided; your exam score must meet or exceed the cut-off score in order to receive the ACPE and BCP Recertification credit.
  • Learners who do not achieve a passing score on a post-activity assessment may appeal assessment questions and/or take a remediation assessment. View AAPP's Post-Activity Assessment Appeal and Remediation Policy.
  • Provide the necessary details in your profile to ensure correct reporting by AAPP to CPE Monitor.

Continuing Education Credit and Disclosures

Activity Dates: 12/11/2025 - 06/11/2026
ACPE Contact Hours: 5
ACPE Numbers: 0284-0000-25-034-H01-P (Application), 0284-0000-25-035-H01-P (Application), 0284-0000-25-036-H01-P (Application), 0284-0000-25-037-H01-P (Application)
Nursing Credit Reminder: Note that ACPE credit is accepted for ANCC Certification Renewal and AANPCB advanced practice provider content. For specific questions related to your organization's acceptance of ACPE continuing education units, please contact your organization directly.

ACPEThe American Association of Psychiatric Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The Psychopharmacology Pearls product is an application-based program approved for 5 ACPE contact hours. To receive ACPE credit, pharmacists completing this programming are required to complete an evaluation of the course as well as pass an online examination.

Board Certified Psychiatric Pharmacists (BCPPs) may also receive 5 hours of BCPP Recertification Credit for the Psychopharmacology Pearls upon successful completion of an online examination.
 
The American Association of Psychiatric Pharmacists is approved as a Professional Development Provider for the Board Certified Psychiatric Pharmacist (BCPP) specialty by the Board of Pharmacy Specialties (BPS). This course is part of a 5 hour BCPP recertification product earned after successful completion of the associated BCPP recertification examination for the full product.
 
AAPP reports continuing credit for ACPE (CPE Monitor) and BCPP Recertification (BPS) within days of successful exam completion.

View AAPP's Privacy Policy

AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.

Questions? Contact AAPP.

View planning committee disclosures

2025 Psychopharmacology Pearls Editorial Board

Beth DeJongh, PharmD, BCPS, BCPP
Director of Continuing Professional Development
American Association of Psychiatric Pharmacists
Lincoln, NE
No Relevant Financial Relationships to Disclose
 
Megan Ehret, PharmD, MS, BCPP
Professor
Monrovia, MD
External Consultant Activities, Advisory Panels, Speakers Bureaus, etc.: Saladex Biomedical Consultant,
Lexi-Comp Consultant/Reviewer, SMI Adviser; Pharmacist Consultant
Educational Grants, Research Grants or Contracts: FDA/University of Maryland CERSI, Maryland Behavioral
Health Department, NIH
 
Beth Hall, PharmD, BCPP
340B Coordinator
Blessing Hospital
Fulton, MO
No Relevant Financial Relationships to Disclose
 
Kayla Johnson, PharmD, BCPP, BCPS
Clinical Pharmacist Specialist
Vanderbilt University Medical Center
Thompsons Station, TN
External Consultant Activities, Advisory Panels, Speakers Bureaus, etc.: Pharmacy Times Continuing Education Speaker
 
Erin Knox, PharmD, BCPP
Director of Experiential Education
UCI School of Pharmacy & Pharmaceutical Sciences
Irvine, CA
No Relevant Financial Relationships to Disclose
 
Michael McGuire, PharmD, BCPP
Associate Professor of Pharmacy Practice
Belmont University College of Pharmacy
Nashville, TN
External Consultant Activities, Advisory Panels, Speakers Bureaus, etc.: Alkermes Inc.
Non-Financial Interests: AAPP Foundation Board of Directors
 
Sandy Mitchell, PharmD, BCPP
Clinical Pharmacy Specialist - Psychiatry
VCU Health System
Richmond, VA
External Consultant Activities, Advisory Panels, Speakers Bureaus, etc.: Wolters Kluwer Consultant
 
Rebecca "Becky" Reiss, PharmD, BCPP
Behavioral Health Clinical Pharmacist Specialist
Denver Health Medical Center
Denver, CO
No Relevant Financial Relationships to Disclose

All relevant relationships have been mitigated.

View independent reviewer disclosures

The articles in this learning activity were developed by the authors in conjunction with the planning committee. Each article subsequently was peer-reviewed and copyedited by the Mental Health Clinician (MHC) prior to publication. As a scholarly journal, the MHC utilizes external double-blind peer review such that reviewer details are not presented here. MHC Editorial Board policies are online.

All relevant relationships have been mitigated.

View disclaimer and disclosure of off-label use

Off-Label Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA (see faculty information). The opinions expressed in the educational activity do not necessarily represent the views of AAPP and any educational partners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

View fair balance and integrity statement

It is the policy of AAPP to ensure independence, balance, objectivity, scientific rigor, and integrity in continuing education activities. Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer’s package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.

Fair balance is achieved through ongoing and thorough review of all materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings. Approval of credit for this continuing education activity does not imply endorsement by AAPP for any product or manufacturer identified.